Investors

Overview

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$3.80 + 0.09 (2.43%)
Day High:$3.84
Day Low:$3.69
Volume:832,716
02/23/184:00 p.m. ET
Delayed at least 15 minutes.

Ed Bell
T +1 206-272-4345
invest@ctibiopharma.com


 

Recent News

MORE
DateTitle 
Feb 14, 2018CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
SEATTLE, Feb. 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY on Thursday, February 15, 2018 at 2:30 PM ET and host one-on-one meetings. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma Corp. CTI BioPharma Corp. is a biopharm... 
Printer Friendly Version
Feb 13, 2018CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
SEATTLE, Feb. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. ("CTI BioPharma") (NASDAQ: CTIC) today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, the underwriters exercised in full their option to purchase 3,000,000 additional shares of common stock at the public offering price, less the underwriting discount. The expected proceeds to CTI BioPha... 
Printer Friendly Version
Feb 09, 2018CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock
SEATTLE, Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPharma has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less the underwriting discount. Proceeds to CTI BioPharma from the offeri... 
Printer Friendly Version

Events

MORE
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.